Replies to post #471625 on NorthWest Biotherapeutics Inc (NWBO)

[rogers5729]

Can we stop saying “comparative increase” of what we’re citing isn’t the increase? The slides from the presentation made this same mistake and it’s infuriating.

Let’s simplify numbers: if you have 5% survival from other trials and then 10% survival in the trial. Then it has doubled. Just like with a stock, that’s a 100% increase not 200%.

Let’s please get our math and phrasing correct.

[Evaluate]

you wrote:

but it’s better than that:

A comparative increase would be 169%
13.2 is 169% of 7.8 if you are talking about OS in recurrent.
DCVax-L OS is 169% of SOC OS for recurrent GBM.

I do not see where you get the 13.2% nor the 7.8% as it relates to recurrent GBM.

Instead, on slide 40 Survival Tail In Recurrent GBM (https://virtualtrials.org/dcvax/dcvax.pdf) it shows:

30 month survival;
DCVax-L: 11.1%
External (controls): 5.1%
11.1% less 5.1% = 6.0% improvement
6.0% improvement divided by the original 5.1% = 117% improvement.